---
title: "FB Financial, Smith Micro Software And 3 Stocks To Watch Heading Into Monday"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/292449183.md"
description: "U.S. stock futures are down on Monday, with several stocks drawing investor attention. FB Financial is set to report quarterly earnings after the close. Smith Micro Software filed a prospectus for a share offering. LogProstyle is expected to release full-year fiscal results before market open. Veraxa Biotech appointed Carl von Halem as interim CFO. Q32 Bio will announce Phase 2a clinical trial results."
datetime: "2026-07-13T06:35:58.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/292449183.md)
  - [en](https://longbridge.com/en/news/292449183.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/292449183.md)
---

# FB Financial, Smith Micro Software And 3 Stocks To Watch Heading Into Monday

With U.S. stock futures trading lower this morning on Monday, some of the stocks that may grab investor focus today are as follows:

-   Wall Street expects **FB Financial Corp.** (NYSE:FBK) to post quarterly earnings of $1.15 per share on revenue of $177.99 million after the close, according to data from Benzinga Pro. FB Financial shares fell 0.1% to $56.60 in after-hours trading.
-   **Smith Micro Software Inc.** (NASDAQ:SMSI) announced it filed a prospectus for an offering of 487,349 shares on behalf of a selling shareholder. Smith Micro Software shares gained 0.8% to close at $2.68 on Friday.
-   **LogProstyle Inc.** (NYSE:LGPS) is projected to report earnings results for the full fiscal year ended March 31, before the opening bell today. LogProstyle shares gained 4.4% to close at $0.83 on Friday.

_Check out our premarket coverage here_

-   **Veraxa Biotech AG** (NASDAQ:VRXA) named Carl von Halem as interim chief financial officer and successor to Torsten Bürgermeister. Veraxa Biotech shares dipped 11.3% to close at $2.20 on Friday.
-   **Q32 Bio Inc.** (NASDAQ:QTTB) said it will report 36-week topline results from Part B of the SIGNAL-AA Phase 2a clinical trial on Monday. Q32 Bio shares tumbled 11% to close at $11.21 on Friday.

_Photo via Shutterstock_

### Related Stocks

- [LGPS.US](https://longbridge.com/en/quote/LGPS.US.md)
- [VRXA.US](https://longbridge.com/en/quote/VRXA.US.md)
- [QTTB.US](https://longbridge.com/en/quote/QTTB.US.md)
- [SMSI.US](https://longbridge.com/en/quote/SMSI.US.md)
- [FBK.US](https://longbridge.com/en/quote/FBK.US.md)

## Related News & Research

- [Veraxa Biotech files first BiTAC-related patent applications for cancer therapy platforms](https://longbridge.com/en/news/294550628.md)
- [Q32 Bio Q2 FY26 net loss narrows to $8.95 million](https://longbridge.com/en/news/294953860.md)
- [Here’s How Much You Would Have Made Owning iShares Gold Trust Micro Shares Stock In The Last 5 Years](https://longbridge.com/en/news/294719493.md)
- [Raab & Moskowitz Asset Management LLC Cuts Stock Position in Advanced Micro Devices, Inc. $AMD](https://longbridge.com/en/news/294580712.md)
- [Stableford Capital II LLC Sells 3,992 Shares of Advanced Micro Devices, Inc. $AMD](https://longbridge.com/en/news/294805791.md)